The sale was executed to cover tax withholding obligations related to the vesting of Restricted Stock Units, as mandated by Twist Bioscience (NASDAQ:)’s equity incentive plans. This “sell to cover” transaction was not a discretionary trade by Cho. InvestingPro analysis indicates the company maintains strong financial health with a current ratio of 4.88 and operates with moderate debt levels. Investors seeking deeper insights can access comprehensive analysis and 8 additional ProTips through InvestingPro’s detailed research reports, available for over 1,400 US stocks including TWST. InvestingPro analysis indicates the company maintains strong financial health with a current ratio of 4.88 and operates with moderate debt levels. Investors seeking deeper insights can access comprehensive analysis and 8 additional ProTips through InvestingPro’s detailed research reports, available for over 1,400 US stocks including TWST.
The sale was executed to cover tax withholding obligations related to the vesting of Restricted Stock Units, as mandated by Twist Bioscience’s equity incentive plans. This “sell to cover” transaction was not a discretionary trade by Cho.
In other recent news, Twist Bioscience has been making significant strides in its financial performance. The company’s fiscal year 2024 concluded on a high note with a 27% increase in Q4 revenues to $84.7 million, and a total annual revenue growth of 28% reaching $330 million. Additionally, the company exceeded its gross margin guidance for the quarter, achieving 45.1%, and saw an annual gross margin improvement to 42.6%.
Baird, TD Cowen, and Scotiabank (TSX:) have all reaffirmed positive ratings on Twist Bioscience, with Baird maintaining an Outperform rating and TD Cowen keeping a Buy rating. Scotiabank has maintained a Sector Outperform rating while raising its price target for the company to $54.
These recent developments highlight the strong demand for Twist Bioscience’s offerings, particularly in the academic and industry sectors. The company’s initial guidance for FY25 anticipates revenue growth between 17% to 20% year-over-year, largely driven by the Next (LON:) Generation Sequencing (NGS) and Synthetic Biology (SynBio) sectors. Twist Bioscience is also expected to improve its adjusted EBITDA by roughly $30 million year-over-year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
